We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Bee Venom Nanoparticles Reduce Tumors in Animal Experiments

By LabMedica International staff writers
Posted on 25 Aug 2009
Melittin, the toxic component of bee venom, has been incorporated into nanoparticles such that when injected into mice triggered death of cancer cells and remission of tumors of both breast cancers and melanomas as well as destruction of precancerous skin lesions. More...
Melittin, a peptide consisting of 26 amino acids, is the principal active component of bee venom (apitoxin) and is a potent antimicrobial compound and a powerful stimulator of phospholipase A2.

Investigators at Washington University School of Medicine (St. Louis, MO, USA) affectionately nicknamed the nanoparticles prepared from perfluorocarbon and melittin "nanobees.” These particles could be further modified to incorporate specific targeting molecules such as antibodies or receptors. The nanobee format has two major features. It sequesters the melittin and protects the body from its toxic effects. At the same time, the nanoparticles are resistant to the action of proteolytic enzymes in the blood that would otherwise quickly destroy the melittin.

To test the efficacy of the nanobees the investigators worked with mouse models for both human breast cancer and melanoma. Results published in the August 10, 2009, online edition of the Journal of Clinical Investigation revealed that four to five injections of generic nanobees over several days, slowed growth of breast cancer tumors by nearly 25%, while the size of melanoma tumors decreased by 88% compared to untreated tumors. Molecularly targeted nanobees selectively delivered melittin to multiple tumor targets, including endothelial and cancer cells. The transfer process did not disrupt the surface membrane of cells but did trigger apoptosis and in animals caused regression of precancerous dysplastic lesions.

"Melittin has been of interest to researchers because in high enough concentration it can destroy any cell it comes into contact with, making it an effective antibacterial and antifungal agent and potentially an anticancer agent," said senior author Dr. Paul Schlesinger, associate professor of cell biology and physiology at Washington University School of Medicine. "Cancer cells can adapt and develop resistance to many anticancer agents that alter gene function or target a cell's DNA, but it is hard for cells to find a way around the mechanism that melittin uses to kill."

"Nanobees are an effective way to package the useful, but potentially deadly, melittin, sequestering it so that it neither harms normal cells nor gets degraded before it reaches its target," said Dr. Schlesinger. "Potentially, these could be formulated for a particular patient. We are learning more and more about tumor biology, and that knowledge could soon allow us to create nanoparticles targeted for specific tumors using the nanobee approach."

Related Links:
Washington University School of Medicine




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.